BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 16675258)

  • 21. Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques.
    Paparella D; Galeone A; Venneri MT; Coviello M; Scrascia G; Marraudino N; Quaranta M; de Luca Tupputi Schinosa L; Brister SJ
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):290-7. PubMed ID: 16434256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of off-pump coronary artery bypass grafting on platelet activation in patients on aspirin therapy until surgery day.
    Suwalski G; Suwalski P; Filipiak KJ; Postuła M; Majstrak F; Opolski G
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):365-9; discussion 369. PubMed ID: 18550381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study.
    Tobe CE; Vocelka C; Sepulvada R; Gillis B; Nessly M; Verrier ED; Hofer BO
    J Thorac Cardiovasc Surg; 1993 Jun; 105(6):1007-13; discussion 1013-4. PubMed ID: 8501929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial.
    Alvarez JM; Jackson LR; Chatwin C; Smolich JJ
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):457-63. PubMed ID: 11547294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
    Fish KJ; Sarnquist FH; van Steennis C; Mitchell RS; Hilberman M; Jamieson SW; Linet OI; Miller DC
    J Thorac Cardiovasc Surg; 1986 Mar; 91(3):436-42. PubMed ID: 3512919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study.
    Aldea GS; Doursounian M; O'Gara P; Treanor P; Shapira OM; Lazar HL; Shemin RJ
    Ann Thorac Surg; 1996 Aug; 62(2):410-7; discussion 417-8. PubMed ID: 8694599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery.
    Shim JK; Choi YS; Oh YJ; Bang SO; Yoo KJ; Kwak YL
    J Thorac Cardiovasc Surg; 2007 Jul; 134(1):59-64. PubMed ID: 17599487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
    Poston RS; White C; Gu J; Brown J; Gammie J; Pierson RN; Lee A; Connerney I; Avari T; Christenson R; Tandry U; Griffith BP
    Ann Thorac Surg; 2006 Jan; 81(1):104-10; discussion 110-1. PubMed ID: 16368345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
    Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
    J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
    Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
    Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet-monocyte pro-coagulant interactions in on-pump coronary surgery.
    Weerasinghe A; Athanasiou T; Philippidis P; Day J; Mandal K; Warren O; Anderson J; Taylor K
    Eur J Cardiothorac Surg; 2006 Mar; 29(3):312-8. PubMed ID: 16423536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
    Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
    Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost.
    Palatianos GM; Foroulis CN; Vassili MI; Matsouka P; Astras GM; Kantidakis GH; Iliopoulou E; Melissari EN
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):548-54. PubMed ID: 14762367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system.
    Wippermann J; Albes JM; Hartrumpf M; Kaluza M; Vollandt R; Bruhin R; Wahlers T
    Eur J Cardiothorac Surg; 2005 Jul; 28(1):127-32. PubMed ID: 15939621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.